Kyle J. Rehrauer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kyle J. Rehrauer has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Adrian E. Roitberg
University of Florida
1 shared publication - Alexander J. Grenning
University of Minnesota
1 shared publication - Anghelo Josh Gangano
Department of Chemistry, University of Florida, P.O. Box 117200, Gainesville, Florida 32611, United States
1 shared publication - Christopher W. Cunningham
Department of Pharmaceutical Sciences, Concordia University Wisconsin, Mequon, Wisconsin 53097, United States
1 shared publication - Daniel G. Barrus
Analytical Chemistry and Pharmaceutics, RTI International, Research Triangle Park, North Carolina 27709, United States
1 shared publication Emily K. Tracy
Analytical Chemistry and Pharmaceutics, RTI International, Research Triangle Park, North Carolina 27709, United States
1 shared publication
Latest Publications
- Open Access
- 14 June 2023
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 145 (25) , 13581-13591
Axially Chiral Cannabinoids: Design, Synthesis, and Cannabinoid Receptor Affinity
The resorcinol-terpene phytocannabinoid template is a privileged scaffold for the development of diverse therapeutics targeting the endocannabinoid system. Axially chiral cannabinols (axCBNs) are unnatural cannabinols (CBNs) that bear an additional C10 substituent, which twists the cannabinol biaryl framework out of planarity creating an axis of chirality. This unique structural modification is hypothesized to enhance both the physical and biological properties of cannabinoid ligands, thus ushering in the next generation of endocannabinoid system chemical probes and cannabinoid-inspired leads for drug development. In this full report, we describe the philosophy guiding the design of axCBNs as well as several synthetic strategies for their construction. We also introduce a second class of axially chiral cannabinoids inspired by cannabidiol (CBD), termed axially chiral cannabidiols (axCBDs). Finally, we provide an analysis of axially chiral cannabinoid (axCannabinoid) atropisomerism, which spans two classes (class 1 and 3 atropisomers), and provide first evidence that axCannabinoids retain─and in some cases, strengthen─affinity and functional activity at cannabinoid receptors. Together, these findings present a promising new direction for the design of novel cannabinoid ligands for drug discovery and exploration of the complex endocannabinoid system.
- 14 June 2023
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 145 (25) , 13581-13591
Open AccessAxially Chiral Cannabinoids: Design, Synthesis, and Cannabinoid Receptor Affinity
The resorcinol-terpene phytocannabinoid template is a privileged scaffold for the development of diverse therapeutics targeting the endocannabinoid system. Axially chiral cannabinols (axCBNs) are unnatural cannabinols (CBNs) that bear an additional C10 substituent, which twists the cannabinol biaryl framework out of planarity creating an axis of chirality. This unique structural modification is hypothesized to enhance both the physical and biological properties of cannabinoid ligands, thus ushering in the next generation of endocannabinoid system chemical probes and cannabinoid-inspired leads for drug development. In this full report, we describe the philosophy guiding the design of axCBNs as well as several synthetic strategies for their construction. We also introduce a second class of axially chiral cannabinoids inspired by cannabidiol (CBD), termed axially chiral cannabidiols (axCBDs). Finally, we provide an analysis of axially chiral cannabinoid (axCannabinoid) atropisomerism, which spans two classes (class 1 and 3 atropisomers), and provide first evidence that axCannabinoids retain─and in some cases, strengthen─affinity and functional activity at cannabinoid receptors. Together, these findings present a promising new direction for the design of novel cannabinoid ligands for drug discovery and exploration of the complex endocannabinoid system.